-
An investigation of the efficacy of polyvalent mastitis vaccine using different vaccination regimens under field conditions in the United Kingdom.
Bradley, A.; Journal of Dairy Sci., Jan 2015.
Analysis of milk production data after the use of a commercially available vaccine against mastitis, demonstrated a return on investment of 2.6 to 1 based on milk yield alone.
-
Case study, controlling clinical mastitis in a dairy herd using a multivalent vaccine.
May, T. W.; NMC 2013.
Increase of animals with SCC < 200.000, decrease of clinical mastitis rate, incidence of mastitis must be reduced by 10 cases per 100 cows per year in order to cover the costs of vaccination. -
Assessment of the use of STARTVAC® vaccine on a dairy farm affected by environmental mastitis.
Ribeiro, C.; STARTVAC® Library 2013.
Reduction of intramammary antibiotic treatment costs and decrease of BTSCC from 446.000 to 239.000. -
Case study, use of vaccination to control bovine mastitis caused by Staphylococcus aureus.
Ortega, R.; NMC 2013.
Increase of cure rate after dry-off with vaccination classic protocol, decrease of S. aureus prevalence 30% to 1,26%, BTSCC decrease and reduction in treatment costs in 50%. -
Case study, practical aproach for lowering the incidence of mastitis and the use of antibiotics on a dairy farm in Flanders.
Tacken, G.; NMC 2013.
Results were much less cases of acute severe mastitis, SCC reduction, culling rate reduction and reduction of mortalility, reduction in milk losses and treatment costs. -
Economic impact of STARTVAC® use in a portuguese dairy herd.
Gonçalves, E. P.; WBC 2012.
Improvement in BTSCC, reduction in number of infected quarters and animals deaths and increase in net profit. -
A partial budget analysis to estimate the economics of mastitis vaccination program.
Lago, A.; WBC 2012.
Overall net profit of the vaccination intervention was EUR 25 per cow in the first 130 days.
